▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Market Now

Kolon Life Science cinches US$591.6m license deal in Japan

  • PUBLISHED :November 19, 2018 - 13:06
  • UPDATED :November 19, 2018 - 13:06
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[DISCLOSURE] Kolon Life Science (102940) announced on Nov. 19 that it has signed a US$591.60 million contract with Mundipharma Medical Company licensing technologies of Invossa-K in Japan.

This amounts to 565 percent of its 2017 revenue and the contract is valid for 15 years from launching the therapy in Japan.

By Hwang You-mee (glamazon@heraldcorp.com)

EDITOR'S PICKS